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We have developed a way to measure cell surface pH by positioning
a pH-sensitive fluorescent dye, seminaphtharhodafluor (SNARF),
conjugated to the pH low insertion peptide (pHLIP). It has been
observed that many diseased tissues are acidic and that tumors are
especially so. A combination of effects acidifies tumor cell interiors,
and cells pump out lactic acid and protons to maintain intracellular
pH, acidifying the extracellular space. Overexpression of carbonic
anhydrases on cell surfaces further contributes to acidification. Thus,
the pH near tumor cell surfaces is expected to be low and to increase
with distance from the membrane, so bulk pH measurements will
not report surface acidity. Our new surface pH-measurement tool
was validated in cancer cells grown in spheroids, in mouse tumor
models in vivo, and in excised tumors. We found that the surface pH
is sensitive to cell glycolytic activity: the pH decreases in high glu-
cose and increases if glucose is replaced with nonmetabolized
deoxyglucose. For highly metastatic cancer cells, the pH measured
at the surface was 6.7–6.8, when the surrounding external pH was
7.4. The approach is sensitive enough to detect 0.2–0.3 pH unit
changes in vivo in tumors induced by i.p. injection of glucose. The
pH at the surfaces of highly metastatic cells within tumors was
found to be about 6.1–6.4, whereas in nonmetastatic tumors, it
was 6.7–6.9, possibly creating a way to distinguish more aggressive
from less aggressive tumors. Other biological roles of surface acidity
may be found, now that targeted measurements are possible.
pH low insertion peptide | tumor acidity | fluorescence | SNARF
In this paper, we report a method that allows targeted measure-ment of cell surface pH in diseased tissues and ex vivo specimens
for the first time to our knowledge. Extracellular acidity is associated
with the development of various pathological states, such as those
in tumors, ischemic stroke, neurotrauma, epileptic seizure,
inflammation, infection, wounds, and others (1–3). Insights and
therapeutic strategies might be gained by measuring pH with
accuracy, precision, and high-spatiotemporal resolution in cell
cultures, animal models, and in humans. Extracellular acidosis
originates from enhanced glucose uptake and metabolism,
known as the Warburg effect. An enhanced use of glycolysis
produces cytoplasmic lactic acid and protons, which are in-
tensively pumped out of cells to keep the intracellular pH near
neutral (4–6). Carbonic anhydrases on the surfaces of cancer
cells further contribute to an acidification of the environment (7,
8). As a consequence, a reversed membrane pH gradient is
formed: the extracellular pH surrounding a cancer cell is lower
than the intracellular pH, which is opposite to the gradient in
normal cells in healthy tissue (9, 10). The average, bulk extra-
cellular pH in tumors is just 0.5–0.8 pH units lower than the
extracellular pH in healthy tissue (11); however, the pH is at its
lowest at the surfaces of cells (12) and increases with distance
from the cellular membrane, becoming normal in the vicinity of
blood vessels (13). Thus, the average pH in tissue is less in-
formative regarding cell metabolism than the pH at cell surfaces.
In vivo magnetic resonance spectroscopy (MRS) and MRI have
been used to monitor tissue pH changes by using endogenous and
exogenous nuclear MR–active compounds (14, 15). Tumor pH has
also been measured using hyperpolarized [13C]bicarbonate (16, 17).
However, these methods are limited in spatial resolution and
cannot measure pH on a cellular level, where optical approaches
must be used. Attempts have been made to use fluorescence im-
aging to study pH near the surface of cultured cancer cells and to
monitor behavior of individual fluorescent cancer cells in the
heterogeneous microenvironments of tumors (18–22), but in most
cases, the pH-sensitive agents were small molecules distributed in
an entire organ/tissue and in blood (where the pH is normal) and
were washed out from the body very quickly. In other cases,
nanocarriers were used (nanoparticles or bacteriophage particles),
but cells internalize them readily via endocytotic pathways, so the
pH could be reported predominately in endosomes (21). The use
of antibody- or receptor-targeting peptides/molecules would also
lead to the probes’ internalization and removing them from the
surface. To measure pH on the surfaces of individual cells, the pH-
sensitive probe needs to be located close to the plasma membrane.
Lipids or fatty acids conjugated with pH-sensitive probes (19, 23)
could be used for pH measurements on a cellular level, but the
probes are not selective for cells in a diseased tissue and will in-
corporate into any cellular membrane. Furthermore, the probes
can readily undergo flipping and participate in lipid exchange, thus
making the identification of their exact location problematic, es-
pecially in experiments in vivo.
We present a novel approach to pH measurements at the sur-
faces of cells in diseased tissues, based on the use of a pH-sensitive
fluorescent dye, seminaphtharhodafluor (SNARF), conjugated to
the Lys residues at the N-terminus of a pH low insertion peptide
(pHLIP). Peptides of the pHLIP family insert across cell mem-
branes in a pH-dependent manner, with their N-termini exposed to
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the extracellular space and their C-termini in the cytoplasm (24–27).
The molecular mechanism of a pHLIP action is based on the
protonation of Asp/Glu residues, which enhances peptide hydro-
phobicity and promotes membrane-associated folding and insertion
of a transmembrane helix (28, 29). pHLIPs labeled with optical,
PET or single-photon emission computed tomography probes target
acidic diseased tissue and are considered to be novel acidity markers
(30–37). The tool we present here for measuring the pH at the
extracellular surface of a cell might contribute to understanding
disease progression and to the development of approaches using
pH-based, image-guided interventions.
Results
We have developed a tool for pH measurement at the surfaces of
cells and validated it on liposomes in vitro, on tumor spheroids grown
from different cancer cell lines, using mouse tumor models in vivo,
and on human tumor tissue samples examined ex vivo. As noted
above, we are using a pHLIP to target and localize a pH-sensitive dye
at the surface of a tumor cell. In addition to the titratable groups in
the transmembrane region, the pHLIP has multiple protonatable
residues at its membrane-inserting C-terminal end, which are
deprotonated in the cytoplasm and serve as additional anchoring
points for the peptide in membrane. Thus, once pHLIP is inserted
into a plasma membrane, the rate of its exit from membrane is very
low even when the extracellular pH is raised, creating an opportunity
to treat cells with the pHLIP at low pH and then to raise the ex-
tracellular for measurements. The N-terminus of the peptide was
acetylated and the adjacent sequence contained a single Lys residue,
allowing specific conjugation with a SNARF-1 dye, followed by ac-
tivation of SNARF-1 at a highly basic pH to obtain SNARF-pHLIP.
The product was purified and characterized.
The ratiometric pH indicator SNARF allows pH to be measured
independently of the dye’s concentration, by comparing the fluores-
cence peaks at two wavelengths. The dye has been used previously to
measure pH in vivo (22). The SNARF-pHLIP was excited by the
xenon lamp attached to an inverted epifluorescence microscope in
the range of 531 ± 20 nm, as selected by an excitation filter. The
fluorescence was selected by an emission cutoff filter for the detection
of light at wavelengths longer than 580 nm. By connecting a spec-
trograph to the microscope, we were able to record the entire fluo-
rescence spectrum of SNARF from 500 to 800 nm simultaneously.
The spectra were analyzed to establish the ratio of emission at 595 to
that at 645 nm. In contrast to the acquisition of separate images at the
two wavelengths via different filters, measurements of continuous
spectra allow us to simultaneously visualize changes in the spectral
components of protonated and deprotonated forms of the SNARF
dye and avoids any potential problems related to photobleaching
because both peaks would decrease proportionally and their ratio
would not change.
We grew tumor spheroids from the highly metastatic human
cervical adenocarcinoma, HeLa, and two human melanoma cell
lines, M4A4 and NM2C5, where M4A4 is highly metastatic,
whereas NM2C5 is nonmetastatic (38, 39). Fig. 1 A and B shows
representative fluorescence images obtained via two different fil-
ter sets of a tumor spheroid stained with the SNARF-pHLIP. Fig.
1C shows the same spheroid stained with DAPI to visualize cell
nuclei. Because our main goal was to measure pH at the surfaces
of cells, we had to prove that SNARF is indeed located in the
extracellular space, and not taken up by endocytosis. We imaged
cells in HeLa tumor spheroids before (Fig. 1D) and immediately
after (Fig. 1E) treatment with Trypan blue, which is membrane-
impermeable and capable of quenching the emission of fluo-
rophores in the range of 500–600 nm (40). The fluorescence of the
SNARF-pHLIP in this region was completely quenched, in-
dicating that SNARF is located in the extracellular space. The
spectra of the SNARF-pHLIP before and after addition of Trypan
blue are shown on Fig. 1F (the emission at 680 nm is associated
with Trypan blue, and the vast majority of cells were viable).
It was necessary to create a calibration curve to convert 595/645 nm
ratio values into pH values. The ratio of emission at 595 to 645 nm
was calculated from the fluorescence spectra of the SNARF-pHLIP
bound to 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
liposomes at various pH values, which were recorded under a mi-
croscope (using exactly the same settings as in other experiments)
(Fig. 2A). The ratios established a calibration curve (Fig. 2B). Upon
mixing, the pH equilibrates rapidly in the solution, at the surfaces of
liposomes, where most of the SNARF-pHLIP is located, and inside
the liposomes (29, 41). From the curve, we obtain:
pH= ð8.459± 0.031Þ− ð1.223± 0.024Þ× ratio595=645. (1)
To confirm that the calibration curve obtained on liposomes is
applicable to cells, tumor spheroids were treated with 50 mM 2-
deoxyglucose (2DG), a nonmetabolizable analog of glucose that
inhibits fermentative metabolism and hence the proton production
and proton flux, as confirmed previously using the Seahorse
extracellular flux analyzer (42). As expected, all three cell lines
grown in spheroids and treated with 2DG exhibited the same ratio
of fluorescence at 595/645 nm, coinciding with the ratios obtained
on liposomes (Fig. 2C).
The calibrated SNARF-pHLIP was used to measure pH at
the surface of metastatic (HeLa and M4A4) and nonmetastatic
(NM2C5) cancer cells grown in tumor spheroids in the presence of
50 mM glucose, which enhances and promotes cellular metabolism
Fig. 1. Images of tumor spheroids and Trypan blue assay. (A and B) Fluo-
rescence images of HeLa tumor spheroids treated with the SNARF-pHLIP at
pH 6.6 were acquired using 580 ± 7 nm (A) and 640 ± 7 nm (B) emission
filters. (C) Each spheroid was then treated with DAPI to stain cell nuclei
(colors are artificial; 10× objective lens). (D and E) The SNARF-pHLIP images
of HeLa tumor spheroids are shown before (D) and immediately after (E) the
addition of 0.67 M of Trypan blue, acquired via a 580 ± 7 nm emission filter.
(F) Spectra of SNARF-pHLIP–treated HeLa tumor spheroids before and after
treatment with Trypan blue.
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(Fig. 2D). Note that the pH at the surface of metastatic cancer
cells does not increase to more than pH 7.0, even when the pH of
the bulk solution is around 7.5. Furthermore, nonmetastatic can-
cer cells are slightly less acidic than metastatic cells, especially in
the range of normal pH values. With a decrease of pH, we ob-
served equilibration of cell surface pH and the bulk external so-
lution at pH ≤ 6.4.
The advantage of our approach is its applicability for pH mea-
surements in vivo, because the pHLIP can target acidic diseased
tissue and tether imaging agents, including fluorescence markers, to
the surfaces of cells (31). To validate this approach in vivo, we grew
tumors in mice using the same cell lines studied in the spheroids
(above): metastatic HeLa and M4A4 and, less metastatic, NM2C5.
When the tumors reached about 5–8 mm in diameter, food was
withdrawn for 24 h to reduce the supply of glucose to cancer cells
from the blood, thereby increasing tumor pH as much as possible,
followed by a single i.v. injection of the SNARF-pHLIP construct.
At 4 h postinjection, the mouse was anesthetized and the skin was
removed from the tumor site. Fluorescence spectra and images
were recorded from the tumor surface. Then, each mouse was given
a single i.p. injection of glucose solution. It was shown previously
that the average extracellular pH decreases after glucose adminis-
tration and reaches a minimum level 0.2–0.3 pH units below the
initial value (43). We measured spectral changes for more than
40 min after the injection of glucose (Fig. 3A). The measurements
showed acidification of the tumors, with no further changes after
40 min. Fig. 3B shows the mean of the cellular surface pH in live
animals before and after glucose injection. HeLa tumors were the
most acidic even after the 24 h starvation period. A statistically
significant 0.3 pH unit reduction of the surface pH was observed in
M4A4 metastatic tumors, whereas no significant changes were
monitored for the NM2C5 nonmetastatic tumors after glucose in-
jection. Finally, the animals were euthanized, tumors were excised
and cut in half, and fluorescence was recorded from the centers of
the tumor. The cellular surface pH values in the centers of HeLa,
M4A4, and NM2C5 tumors were found to be 6.5 ± 0.2, 6.7 ± 0.5,
and 6.9 ± 0.3, respectively, with some HeLa and M4A4 tumors
having regions with surface pH values as low as pH 6.0–6.1.
Finally, we analyzed tumor tissues excised from mice, immedi-
ately treated with the SNARF-pHLIP ex vivo for 1 h, extensively
washed with pH 7.4 PBS buffer, and observed using SNARF
fluorescence spectra and images (Fig. 3C). The incubation treat-
ment was performed in the absence and presence of glucose.
Glucose in solution promotes cellular metabolism selectively in
glycolytic, highly metastatic cancer cells and enhances acidity near
cellular surfaces. Thus, pHLIP preferentially inserts into plasma
membrane of cells with low pH at the surface, such as cancer cells.
At the same time, it is known that glucose does not affect signif-
icantly nonglycolytic cells in healthy tissue, which have normal
surface pH (44). The mean values of the cellular surface pH in
highly metastatic human HeLa and murine 4T1 mammary tumor
samples in the absence and presence of glucose are shown in Fig.
3D. The measured surface pH was lowered by 0.7 and 0.3 pH units
from pH 6.8 ± 0.2 to pH 6.1 ± 0.3 and from pH 6.7 ± 0.4 to pH 6.4 ±
0.4 in the 4T1 and HeLa tumor samples, respectively.
Discussion
Hypoxic conditions induce a switch from the oxidative–phosphory-
lation mechanism of energy production to glycolysis. In addition,
Fig. 2. Calibration curves and pH at the surfaces of cancer cells in tumor
spheroids. (A) Emission spectra at different pH values of liposomes treated
with the SNARF-pHLIP in PBS containing 50 mM 2-DG were recorded using an
inverted epifluorescence microscope connected to a spectrograph. (B) The
calibration curve (red line) and 95% confidence interval (green lines) were
obtained by linear fitting of 595/645 fluorescence ratios (black circles) of the
SNARF-pHLIP bound to POPC liposomes at various pH values. A separate cell-
based calibration curve in 50 mM 2-DG was obtained as a function of pH from
HeLa, M4A4, and NM2C5 cell spheroids treated with the SNARF-pHLIP in PBS.
(C) Shown are the 595/645 nm ratio values and the fit (black line). Cellular
surface pH values in glucose for HeLa, M4A4, and NM2C5 cell spheroids were
then obtained using the calibration spectra. (D) Spheroids were treated with
the SNARF-pHLIP in PBS containing 50 mM glucose at different pH values.
Fig. 3. pH measured at the surfaces of cancer cells in tumors in vivo and ex
vivo. (A) Representative fluorescence spectra recorded from tumors in live
mice (skin is removed from the tumor site) 4 h after administration of
SNARF-pHLIP as a single tail vein injection before and after i.p. injection of
125 mg of glucose. (B) Mean values of cell surface pH at the surface of a
tumor of a live animal before and after injection of glucose (in vivo mea-
surements) and in the middle of the excised tumor after glucose injection (ex
vivo measurements). The number of measurements that were performed on
multiple HeLa tumors before and after glucose injection and in the tumor
center were 24, 30, and 36, respectively; on M4A4 tumors before and after
glucose injection and in the tumor center were 13, 11, and 10, respectively;
and on NM2C5 tumors before and after glucose injection and in the tumor
center were 16, 21, and 8, respectively. **P < 0.005. (C) Representative
fluorescence image obtained from a HeLa tumor specimen treated ex vivo
with the SNARF-pHLIP in the presence of glucose, followed by washing.
(D) Mean values of the surface pH measured ex vivo in HeLa and 4T1 tumor
specimens treated with the SNARF-pHLIP in the absence and presence of
glucose. The measurements performed on the HeLa tumor specimens in the
absence and presence of glucose were 56 and 51, respectively; and on the
4T1 tumor specimens in absence and presence of glucose were 35 and 31,
respectively.

















malignant cancers have an elevated glucose uptake even under nor-
mal oxygen conditions, known as the Warburg effect (4–6). Each of
these mechanisms results in an elevated level of H+ and lactic acid
production in the cytoplasm. To maintain cytoplasmic pH, these
byproducts are pumped across the plasma membrane into the ex-
tracellular space, where they accumulate in poorly perfused regions
such as solid tumors and ischemic stroke lesions (45–48). In tumors,
the rapid metabolism produces high levels of CO2, inducing the ex-
pression of cell surface carbonic anhydrases, which catalyze the pro-
duction of additional extracellular acid by hydrating cell-generated
CO2 into HCO3
− and H+ (7, 8). These mechanisms each contribute
to an acidic extracellular milieu and create an “acidic crown” around
cancer cells that favors tumor development and progression, playing a
role in almost all steps of metastasis: more acidic tumors became
highly aggressive and metastatic (11). The pH near tumor cell sur-
faces is the lowest, and acidity decays with distance (19). Thus, the pH
at cell surfaces can be a measure of the stage of tumor development.
Acidification of extracellular space associated not only with tumor
development but also with other pathological states, such as ischemic
stroke, neurotrauma, epileptic seizure, inflammation, infection,
wounds, and others (1–3). Previously, we have demonstrated tar-
geting of inflammatory arthritis (28) and ischemic myocardium
(34) by fluorescent pHLIPs.
The SNARF-pHLIP tool enables pH measurement at the sur-
faces of cells in acidic diseased tissues. We have validated the
method on metastatic and nonmetastatic cancer cells grown in tu-
mor spheroids and in mouse tumor models. The mean values of pH
at the surfaces of cancer cells in the center of highly metastatic
(HeLa and M4A4) tumors were found to be 6.5–6.7, whereas the
average pH at the surfaces of cancer cells in nonmetastatic tumors
(NM2C5) was 6.9. The values obtained are about 0.2–0.4 pH units
lower than the pH values of the bulk extracellular space measured
by 31P MRS in various mouse and rat tumor models, variously
reported as pH 6.7 to pH 7.0 (the normal tissue pH was established
to be 7.3–7.4) (49). The new measurement is sensitive enough to
detect 0.2 pH unit decreases induced by glucose injection. The
distribution of surface pH within a tumor mass was heterogeneous,
with the lowest values found to be 6.0–6.1. We speculate that these
parts may contain the most aggressive and invasive subpopulation of
cancer cells.
Using our new probe, we have shown that the pH at the surfaces of
cancer cells, especially metastatic cells, can be 0.7–0.9 pH units lower
than the pH, typically 7.4, of the bulk fluids in normal tissues. This
finding indicates that cancer cells can be detected not only in poorly
perfused parts of a diseased tissue but also in well-perfused tissue and
biofluids. An ability to measure surface pH might have clinical ap-
plications for diagnostic surface pH measurements of cancer cells in
human biopsy specimens, blood, and other biofluids. Because surface
acidity correlates with tumor stage and invasiveness, pH measure-
ments may usefully guide therapeutic choices, serve as therapeutic
monitors, or aid therapeutic agent research and development.
Materials and Methods
Peptide Synthesis and Conjugation with Fluorescent Dyes. A pHLIP was syn-
thesized with a single Lys residue near its acetylated N-terminus (Ac-
AKEQNPIYWARYADWLFTTPLLLLDLALLVDADEGT) and purified by reverse-
phase chromatography by CS Bio. SNARF-1 carboxylic acid, acetate, succinimidyl
ester (Life Technologies) were incubated at a ratio of 2:1 with the pHLIP in 60%
(vol/vol) dimethylformamide, 30% (vol/vol) 0.1M PBS pH 9.0, and 10% (vol/vol) pH
9.5 0.1 M sodium bicarbonate buffer for a final pH of 9.0. SNARF-1 was converted
to its fluorescent form after conjugation by raising the conjugation solution’s
volume by 50% (vol/vol) with methanol and raising the solution pH to 12 with
2 M potassium hydroxide for 1 h, then pH was adjusted to 7.0 by adding 1M HCl.
The reaction progress was monitored by reverse-phase (Zorbax SB-C18 col-
umns; 9.4 × 250 mm; 5 μm; Agilent Technology) HPLC using a gradient of
25−75% acetonitrile and water containing 0.05% trifluoroacetic acid. The
concentration of each labeled peptide in buffer was determined by
SNARF-1 absorption at 548 nm, e548 = 27,000 M
−1 cm−1. The purity and
characterization of the constructs was performed by analytical HPLC and
surface-enhanced laser desorption/ionization–TOF mass spectrometry.
Phosphate-Buffered Solutions. Phosphate-buffered solutions were prepared
by mixing 0.5 M dibasic and monobasic solutions (J. T. Baker) to obtain the
desired pH in the range of 5.5–8.0. The final PBS solutions (experimental PBS)
contained 10 mM phosphate, 150 mM NaCl (J. T. Baker), 0.2 mM MgCl2
(Sigma), and 0.2 mM CaCl2 (Sigma). The pH of the final solution was mea-
sured with a microelectrode pH meter (Thermo Scientific). Buffer solutions
were sterilized by passage through a 0.2-μm filter.
Liposome Preparation. Large unilamellar vesicles (LUVs) were prepared by
extrusion; 2.5 mg of POPC (Avanti Polar Lipids) lipids were dissolved in 0.5 mL
of chloroform, desolvated on a rotary evaporator, and dried under high
vacuum for 3 h. The phospholipid film was then rehydrated in pH 7.4 ex-
perimental PBS, vortexed for 5 min, and repeatedly extruded through a
membrane with 50-nm pores to obtain LUVs.
Cell Lines. Human cervical adenocarcinoma HeLa, human melanoma M4A4,
human melanoma NM2C5, and mouse breast cancer 4T1 cell lines were
purchased from the American Tissue and Culture Collection (ATCC). All lines
were propagated in Dulbecco’s modified Eagle medium (DMEM) containing
4.5 g/L D-glucose and 40 mg/L sodium pyruvate supplemented with 10% FBS
(Gibco), ciprofloxacin·HCl (10 μg/mL) (from Cellgro, Voigt Global Distribu-
tion) in a humidified atmosphere of 5% CO2 at 37 °C.
Tumor Spheroids. A total of 150 μL of 1% agarose (Sigma) in 1× strength PBS
pH 7.4 (Gibco) was pipetted into each well of a 48-well flat bottom tissue
culture plate (Celltreat). After the agarose gel had sufficiently settled (∼1 h),
200 μL of DMEM supplemented with 10% FBS, ciprofloxacin·HCl was then
added to each well. The covered tray was then left in a humidified atmo-
sphere at 37 °C, 5% CO2 for 24 h. Next, a suctioned glass Pasteur pipette was
used to remove excess media from the agarose layer. Then, 200 μL of the
same DMEM with 10,000 HeLa, NM2C5, or M4A4 cells were seeded into each
well and kept in a humidified atmosphere of 5% CO2 at 37 °C for 3–4 d.
When matrigel (Corning) was used, it was dissolved on ice in DMEM at a
concentration of 2.5% (to give 2% once added to the wells) and then heated
to 37 °C before being combined with cells to be seeded.
Tumor Mouse Models. All animal studies were conducted according to the
animal protocol AN04-12-011 approved by the Institutional Animal Care and
Use Committee at the University of Rhode Island, in compliance with the
principles and procedures outlined by the NIH for the Care and Use of An-
imals. s.c. tumors were established by injection of HeLa (1.5 × 106 cells per
0.1 mL per flank), M4A4 (1.5 × 106 cells per 0.1 mL per flank), NM2C5 (2 × 106
cells per 0.1 mL per flank), and 4T1 cells (0.8 × 106 cells per 0.1 mL per flank)
in the right flank of adult female athymic nude mice (for implanting of
human cancer cell lines: HeLa, M4A4, and NM2C5) and adult female BALB/c
mice (for implanting of murine cancer cell line 4T1). Mice were about 20−22 g
and were obtained from Harlan Laboratories.
Imaging Tumor Spheroids. The spheroids of a given cell line were incubated
with 5 μM SNARF-pHLIP in 50 μL of experimental PBS buffer (pH 6.3) either
with 25 mM D-glucose (glucose) or 50 mM 2DG, in an open Eppendorf in a
humidified atmosphere of 5% CO2 at 37 °C for 30 min. The spheroids were
then washed three times with 1 mL of experimental PBS of the pH that was
desired for the observation. The spheroids were then placed into an open
Eppendorf with 1 mL of the same PBS, followed by washing with PBS con-
taining either 25 mM glucose or 50 mM 2DG for 15 min. The spheroids were
transferred to a single well of a glass-bottom 96-well cell tray, and the
fluorescence signal was recorded through an inverted epifluorescence mi-
croscope (Olympus IX71) (mostly using a 20× objective lens). Both spectra
and images of the SNARF-pHLIP from tumor spheroids were obtained using
the same excitation filter (FF01-531/40-25; Semrock) with a band of trans-
mittance at 531 ± 20 nm. The fluorescence spectra from tumor spheroids
were recorded by Solis software (Andor) after emission from the sample was
passed through a long-pass emission filter (BCP01-568R-25; Semrock) with
transmittance at 580 nm and higher and a Shamrock SR-303i-B spectrograph
(Andor) with a diffraction grating of 300 lines per millimeter with 500-nm
blaze wavelength, a 400-μm entrance slit, and a NewtonEM electron-multi-
plying CCD camera (Andor) thermoelectrically cooled to −60 °C. Spectra
were taken every several minutes until three in a row were identical at the
noise level. After recording the spectra, fluorescent images of the samples
were acquired using Qcapture software by a Retiga-SRV CCD (Qimaging)
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with two emission filters FF01-580/14-25 (Semrock) and FF01-640/14-25
(Semrock) with transmittance at 580 ± 7 nm and 640 ± 10 nm, respectively.
SNARF-pHLIP Liposome Calibration. A total of 300 μL of 1 μM SNARF-pHLIP and
200 μM POPC liposomes were mixed into pH 7.4 experimental PBS and left to
incubate overnight at 4 °C. The pH was adjusted by adding 0.5 M hydrochloric
acid or 2 M potassium hydroxide, and final pH of the solution was measured
with a microelectrode pH meter (Thermo Scientific). The solution was placed
into a glass-bottom collagen-coated cell dish (MatTek) and imaged on a
fluorescence microscope with an 20× objective lens. Spectra were taken as
described above.
Trypan Blue Assay. Trypan blue solution (Sigma) at a concentration of 0.67 M in
experimental PBS (pH 7.0) was added to a HeLa spheroid, which was incubated
with SNARF-pHLIP as described above, in a glass-bottom collagen-coated cell dish
(MatTek). The fluorescence spectra and images before and immediately after
addition of Trypan bluewere taken as described above using a 20×objective lens.
In Vivo Imaging of Tumors. When tumors reached 5–8 mm in diameter, each
mouse was restricted from eating for 24 h before a single tail vein injection of
4 nmol (100 μL of 40 μM) of SNARF-pHLIP in PBS was performed. At 4 h after
injection, the skin was removed from the tumor site under ketamine/xylazine an-
esthesia, and the mouse tumor was placed onto a 24 × 60-mm No.1 thickness glass
slide and imaged using a fluorescence microscope using a 20× magnification
objective lens, as described above. The SNARF-pHLIP fluorescence spectra and im-
ages were taken from various areas of the tumor before and after an i.p. injection
of 125 mg of glucose (125 mg in 220 μL of PBS pH 7.4). After in vivo imaging, each
animal was euthanized by cervical dislocation, and the tumor was excised and cut
in half, and fluorescence spectra and images were acquired immediately as
described above.
Ex Vivo Imaging of Tumors.When its tumor reached 5–8 mm in diameter, each
mouse was euthanized and the tumor was excised. The tumor was cut into
slices and placed into 150 μL of 1 μM solution of SNARF-pHLIP in PBS (pH 6.3)
with either no glucose or 25 mM glucose. The slices were left to incubate with
SNARF-pHLIP for 1 h and washed three times with 150 μL of experimental PBS
(pH 7.4) with 15 min between washings. The slices were placed into a glass-
bottom dish, and spectra and images were acquired.
Spectra and Image Analysis. The fluorescence spectra were analyzed with a
Mathematica program (Version 10; Wolfram). All graphs were constructed
using Origin Lab (Version 9.1; Origin Lab Corporation). P valueswere computed
based on the two-tailed test.
ACKNOWLEDGMENTS. We thank Dr. Ramona-Cosmina Adochite, Dr. Gregory
Andreev, Mr. Linden Wyatt, and Mr. Da Wei for assistance with the pH-
imaging project. This work was supported by NIH Grants CA174413 (to O.A.A.
and Y.K.R.) and GM073857 (to O.A.A., Y.K.R., and D.M.E.).
1. Pezzulo AA, et al. (2012) Reduced airway surface pH impairs bacterial killing in the
porcine cystic fibrosis lung. Nature 487(7405):109–113.
2. Paschen W, Djuricic B, Mies G, Schmidt-Kastner R, Linn F (1987) Lactate and pH in the brain:
Association and dissociation in different pathophysiological states. J Neurochem 48(1):154–159.
3. Kedika RR, Souza RF, Spechler SJ (2009) Potential anti-inflammatory effects of proton pump
inhibitors: A review and discussion of the clinical implications. Dig Dis Sci 54(11):2312–2317.
4. Warburg O,Wind F, Negelein E (1927) Themetabolism of tumors in the body. J Gen Physiol
8(6):519–530.
5. Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased glucose
metabolism of cancers. J Nucl Med 49(Suppl 2):24S–42S.
6. Newell K, Franchi A, Pouysségur J, Tannock I (1993) Studies with glycolysis-deficient
cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc
Natl Acad Sci USA 90(3):1127–1131.
7. Swietach P, Vaughan-Jones RD, Harris AL (2007) Regulation of tumor pH and the role
of carbonic anhydrase 9. Cancer Metastasis Rev 26(2):299–310.
8. Ihnatko R, et al. (2006) Extracellular acidosis elevates carbonic anhydrase IX in human
glioblastoma cells via transcriptional modulation that does not depend on hypoxia.
Int J Oncol 29(4):1025–1033.
9. Gerweck LE, Seetharaman K (1996) Cellular pH gradient in tumor versus normal tis-
sue: Potential exploitation for the treatment of cancer. Cancer Res 56(6):1194–1198.
10. Raghunand N, et al. (1999) Plasmalemmal pH-gradients in drug-sensitive and drug-
resistant MCF-7 human breast carcinoma xenografts measured by 31P magnetic res-
onance spectroscopy. Biochem Pharmacol 57(3):309–312.
11. Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, Gillies RJ (2011) Imaging pH and
metastasis. NMR Biomed 24(6):582–591.
12. Chiche J, Brahimi-Horn MC, Pouysségur J (2010) Tumour hypoxia induces a metabolic
shift causing acidosis: A common feature in cancer. J Cell Mol Med 14(4):771–794.
13. Parks SK, Chiche J, Pouysségur J (2013) Disrupting proton dynamics and energy me-
tabolism for cancer therapy. Nat Rev Cancer 13(9):611–623.
14. Zhang S, Wu K, Sherry AD (1999) A novel pH-sensitive MRI contrast agent. Angew
Chem Int Ed Engl 38(21):3192–3194.
15. Zhang X, Lin Y, Gillies RJ (2010) Tumor pH and its measurement. J Nucl Med 51(8):1167–1170.
16. Gallagher FA, et al. (2008) Magnetic resonance imaging of pH in vivo using hyperpolarized
13C-labelled bicarbonate. Nature 453(7197):940–943.
17. Gallagher FA, Kettunen MI, Brindle KM (2011) Imaging pH with hyperpolarized 13C.
NMR Biomed 24(8):1006–1015.
18. Helmlinger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid
tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med 3(2):
177–182.
19. Stock C, et al. (2007) pH nanoenvironment at the surface of single melanoma cells.
Cell Physiol Biochem 20(5):679–686.
20. Schreml S, et al. (2011) 2D luminescence imaging of pH in vivo. Proc Natl Acad Sci USA
108(6):2432–2437.
21. Hilderbrand SA, Kelly KA, Niedre M, Weissleder R (2008) Near infrared fluorescence-based
bacteriophage particles for ratiometric pH imaging. Bioconjug Chem 19(8):1635–1639.
22. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ (2006) Acid-mediated tumor
invasion: A multidisciplinary study. Cancer Res 66(10):5216–5223.
23. Ke G, et al. (2014) A cell-surface-anchored ratiometric fluorescent probe for extra-
cellular pH sensing. ACS Appl Mater Interfaces 6(17):15329–15334.
24. Weerakkody D, et al. (2013) Family of pH (low) insertion peptides for tumor target-
ing. Proc Natl Acad Sci USA 110(15):5834–5839.
25. Andreev OA, Engelman DM, Reshetnyak YK (2014) Targeting diseased tissues by
pHLIP insertion at low cell surface pH. Front Physiol 5:97.
26. Reshetnyak YK, Andreev OA, Lehnert U, Engelman DM (2006) Translocation of molecules
into cells by pH-dependent insertion of a transmembrane helix. Proc Natl Acad Sci USA
103(17):6460–6465.
27. Reshetnyak YK, Segala M, Andreev OA, Engelman DM (2007) A monomeric mem-
brane peptide that lives in three worlds: In solution, attached to, and inserted across
lipid bilayers. Biophys J 93(7):2363–2372.
28. Andreev OA, et al. (2007) Mechanism and uses of a membrane peptide that targets
tumors and other acidic tissues in vivo. Proc Natl Acad Sci USA 104(19):7893–7898.
29. Karabadzhak AG, et al. (2012) Modulation of the pHLIP transmembrane helix in-
sertion pathway. Biophys J 102(8):1846–1855.
30. Vavere AL, et al. (2009) A novel technology for the imaging of acidic prostate tumors
by positron emission tomography. Cancer Res 69(10):4510–4516.
31. Reshetnyak YK, et al. (2011) Measuring tumor aggressiveness and targeting meta-
static lesions with fluorescent pHLIP. Mol Imaging Biol 13(6):1146–1156.
32. Daumar P, et al. (2012) Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide
analogues and their biological evaluation. Bioconjug Chem 23(8):1557–1566.
33. Macholl S, et al. (2012) In vivo pH imaging with (99m)Tc-pHLIP. Mol Imaging Biol 14(6):
725–734.
34. Sosunov EA, et al. (2013) pH (low) insertion peptide (pHLIP) targets ischemic myo-
cardium. Proc Natl Acad Sci USA 110(1):82–86.
35. Adochite RC, et al. (2014) Targeting breast tumors with pH (low) insertion peptides.
Mol Pharm 11(8):2896–2905.
36. Cruz-Monserrate Z, et al. (2014) Targeting pancreatic ductal adenocarcinoma acidic
microenvironment. Sci Rep 4:4410.
37. Karabadzhak AG, et al. (2014) pHLIP-FIRE, a cell insertion-triggered fluorescent probe for
imaging tumors demonstrates targeted cargo delivery in vivo.ACS ChemBiol 9(11):2545–2553.
38. Suzuki M, Mose ES, Montel V, Tarin D (2006) Dormant cancer cells retrieved from
metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol
169(2):673–681.
39. Rae JM, et al. (2004) Common origins of MDA-MB-435 cells from various sources with
those shown to have melanoma properties. Clin Exp Metastasis 21(6):543–552.
40. Loike JD, Silverstein SC (1983) A fluorescence quenching technique using trypan blue
to differentiate between attached and ingested glutaraldehyde-fixed red blood cells
in phagocytosing murine macrophages. J Immunol Methods 57(1-3):373–379.
41. Elamrani K, Blume A (1983) Effect of the lipid phase transition on the kinetics of H+/OH-
diffusion across phosphatidic acid bilayers. Biochim Biophys Acta 727(1):22–30.
42. Ibrahim-Hashim A, et al. (2011) Free base lysine increases survival and reduces me-
tastasis in prostate cancer model. J Cancer Sci Ther 4(Suppl 1):JCST-S1-004.
43. Kozin SV, Shkarin P, Gerweck LE (2001) The cell transmembrane pH gradient in tu-
mors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res
61(12):4740–4743.
44. Jähde E, Rajewsky MF (1982) Tumor-selective modification of cellular microenviron-
ment in vivo: Effect of glucose infusion on the pH in normal and malignant rat tissues.
Cancer Res 42(4):1505–1512.
45. Grillon E, et al. (2011) The spatial organization of proton and lactate transport in a rat
brain tumor. PLoS One 6(2):e17416.
46. Rehncrona S (1985) Brain acidosis. Ann Emerg Med 14(8):770–776.
47. Xiong ZG, Pignataro G, Li M, Chang SY, Simon RP (2008) Acid-sensing ion channels
(ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin
Pharmacol 8(1):25–32.
48. Shulman RG, Rothman DL (2015) Homeostasis and the glycogen shunt explains aer-
obic ethanol production in yeast. Proc Natl Acad Sci USA 112(35):10902–10907.
49. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the tumor mi-
croenvironment. J Magn Reson Imaging 16(4):430–450.
Anderson et al. PNAS | July 19, 2016 | vol. 113 | no. 29 | 8181
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
